Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | SREBF2 | Q12772 | 3/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11152023 | 0.85 | RAB9A (0.58) | KDM4ERAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL17336836 | 0.84 | RAB9A (0.75) | KDM4ERAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL3603144 | 0.84 | RAB9A (0.75) | KDM4ERAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL2220170 | 0.84 | SREBF2 (0.70) | KDM4ERAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL7972459 | 0.83 | KDM4E (0.69) | KDM4ERAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL26123239 | 0.83 | KDM4E (0.73) | KDM4ERAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL28493960 | 0.83 | SMN1; SMN2 (0.73) | KDM4ERAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL26118261 | 0.83 | KDM4E (0.73) | KDM4ERAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL7532072 | 0.83 | KDM4E (0.73) | KDM4ERAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL428793 | 0.80 | RAB9A (0.96) | KDM4ERAB9ASMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1781595-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | Praecis Pharmaceuticals Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHAMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006020951-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | KDM4E 3325/4885RAB9A 2800/4885SMN1; SMN2 1924/4885 |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | KDM4E 3325/4885RAB9A 2800/4885SMN1; SMN2 1924/4885 |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | KDM4E 3325/4885RAB9A 2800/4885SMN1; SMN2 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.